You are here

  • Home
  • Archive
  • Volume 14, Issue 5
  • Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

Article Text

Article menu
Download PDFPDF
ORIGINAL ARTICLES
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
  1. L. R. Bigler*,
  2. J. Tate Thigpen†,
  3. J. A. Blessing‡,
  4. J. Fiorica§ and
  5. B. J. Monk
  1. * Department of Medicine, Division of Oncology, University of Mississippi Medical Center, Jackson, MS, USA
  2. † Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
  3. ‡ Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA
  4. § Gynecologic Oncology Program, H. Lee Moffitt Cancer Center, University of Southern Florida, Tampa, FL, USA
  5. Division of Gynecologic Oncology, Chao Comprehensive Cancer Center, University of California at Irvine, Orange, CA, USA
  1. Address correspondence and reprint requests to: J. Tate Thigpen, Department of Medical Oncology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA. Email: jthigpen{at}medicine.umsmed.edu

  • Address for reprints: Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd., Suite 1020, Philadelphia, PA 19103, USA.

Abstract

This study was undertaken to estimate the antitumor activity of tamoxifen in patients with persistent or recurrent nonsquamous cell carcinoma of the cervix. Furthermore, the nature and degree of adverse effects from tamoxifen in this cohort of individuals was examined. Tamoxifen citrate was to be administered at a dose of 10 mg per orally twice a day until disease progression or unacceptable side effects prevented further therapy. A total of 34 patients (median age: 49 years) were registered to this trial; two were declared ineligible. Thirty-two patients were evaluable for adverse effects and 27 were evaluable for response. There were only six grades 3 and 4 adverse effects reported: leukopenia (in one patient), anemia (in two), emesis (in one), gastrointestinal distress (in one), and neuropathy (in one). The objective response rate was 11.1%, with one complete and two partial responses. In conclusion, tamoxifen appears to have minimal activity in nonsquamous cell carcinoma of the cervix.

  • squamous cell carcinoma
  • tamoxifen citrate

https://doi.org/10.1136/ijgc-00009577-200409000-00020

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.